Paul Peloso

Company: COUR Pharmaceuticals

Job title: Chief Medical Officer

Seminars:

Panel Discussion: Shaping the Future of Treg Modulators to Produce Cutting-Edge Therapies 2:30 pm

Exploring novel Treg modulators beyond IL-2 (including IL-35 and TNFR-2 agonists) to uncover new therapeutic capabilities Investigating emerging small molecules and biologic modulators to supercharge therapeutic development Discovering antibody-specific Treg modulationRead more

day: Day 1 Treg Modulatorstrack

Discussing Considerations when Determining Disease Indication 3:00 pm

Exploring disease analysis methods to identify indications in which Tregs can be effectively utilized Effectively unravelling complex mechanisms of action to find an appropriate disease indication Identifying the ideal disease to be tackled by Treg cell therapies and Treg modulatorsRead more

day: Day Two PM